Form 4: SpringWorks Therapeutics Chief Scientific Officer Receives Stock Options and Restricted Stock Units

SpringWorks Therapeutics' Chief Scientific Officer, Tai-An Lin, was granted stock options and restricted stock units on January 10, 2025.

Summary

• Tai-An Lin, the Chief Scientific Officer of SpringWorks Therapeutics, received a grant of 6,929 restricted stock units (RSUs) and stock options for 20,246 shares on January 10, 2025.
• The RSUs will vest in three tranches: 33% on January 10, 2026, 33% on January 10, 2027, and the remaining 34% on January 10, 2028, contingent upon continued service.
• The stock options will vest in 48 equal monthly installments starting after January 10, 2025, also subject to continued service.
• The exercise price for the stock options is $43 per share, and they expire on January 10, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, indicating a positive alignment of interests. The vesting schedule suggests a long-term commitment from the executive.

Positives

• The grant of RSUs and stock options aligns the Chief Scientific Officer's interests with the long-term success of the company.
• The vesting schedule for both RSUs and stock options encourages continued service and commitment from the executive.
• The stock options provide an opportunity for the executive to benefit from potential increases in the company's stock price.

Risks

• The vesting of the RSUs and stock options is contingent upon the executive's continued service, which introduces a risk of forfeiture if employment is terminated.
• The value of the stock options is dependent on the future performance of the company's stock price, which is subject to market fluctuations.

Future Outlook

The vesting of the RSUs and stock options is contingent upon continued service, suggesting the company anticipates the executive's ongoing contribution.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry, similar to companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.
• The vesting schedules are typical, with multi-year vesting periods to ensure long-term commitment, which is comparable to practices at companies like Regeneron Pharmaceuticals.
• The specific amounts and terms of the grants would need to be compared to peer companies to determine if they are above or below industry averages.

Stakeholder Impact

• Shareholders may view the grants positively as they align executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.
• The grants do not have a direct impact on customers, suppliers, or creditors.

Key Dates

Keywords

stock options, restricted stock units, RSUs, executive compensation, insider trading, vesting, SpringWorks Therapeutics, SWTX